Chronos Bio is building the intelligence platform for longevity research. Multi-omics biological age. Senolytic compound screening. Cellular reprogramming design. Compressing decades of aging research into years.
100,000 people die from aging every day. We are building the AI to change that.
Aging kills more people than every other cause combined. Cancer, heart disease, neurodegeneration, diabetes, organ failure -- they are all symptoms of the same underlying process: cellular aging. Yet we spend trillions treating each symptom individually while the root cause goes unaddressed.
The cost is staggering. Age-related diseases consume over $8.3 trillion annually in the US alone -- 80% of all healthcare spending. By 2050, 2.1 billion people will be over 60 (WHO), placing unsustainable strain on every healthcare system on Earth.
The longevity research field is fragmented across thousands of labs, each studying one piece of the aging puzzle in isolation. No platform integrates the 12 hallmarks of aging into a unified model. No tool can screen millions of potential anti-aging compounds computationally. The search space is in the billions -- and researchers test hundreds per year, manually.
Chronos Bio builds the AI platform that every longevity researcher and pharma R&D team needs. Multi-omics biological age intelligence, senolytic compound screening, and cellular reprogramming optimization -- all in one platform.
Multi-Omics Biological Age
Compute biological age from blood biomarkers using multiple published aging clocks. Get a multi-dimensional aging profile: inflammation, metabolic health, immune aging, organ function. Track how interventions change your biological age over time.
AI Compound Screening
Screen any compound for senolytic activity using AI trained on published screening data. Predict mechanism of action, selectivity across senescent cell types, and toxicity. Compare against all known senolytics. Discover novel candidates from millions of molecules.
Cellular Rejuvenation Design
AI-designed reprogramming factor optimization. Following the GPT-4b micro paradigm, use protein language models to design safer, more effective transcription factors for cellular rejuvenation. Optimize multi-factor cocktails for tissue-specific reprogramming.
Sam Altman-backed aging startup. OpenAI/Retro collaboration achieved 50x reprogramming improvement. Dec 2025.
Largest private longevity funding ever. Recruited Steve Horvath and Morgan Levine from top universities.
Largest longevity-specific funding round of 2025. Coinbase CEO Brian Armstrong co-founded.
Ozempic/Wegovy generate $20B+/year. Investors now believe longevity drugs can be blockbusters.
Three converging breakthroughs in 2024-2026 make Chronos Bio possible for the first time. AI can now design better reprogramming factors than humans, predict biological age from multi-omics data, and screen hundreds of thousands of senolytic candidates computationally.
OpenAI + Retro Biosciences, 2025
GPT-4b micro redesigned Yamanaka reprogramming factors with 50x improved efficacy and fewer DNA breaks. AI can now design biological interventions that surpass 20 years of human research. The paradigm shift: AI designs the drugs, not just screens them.
OMICmAge, Nature Aging 2026
Third-generation clocks integrate proteomics, metabolomics, clinical data, and DNA methylation. OMICmAge predicts mortality better than any single-omic clock. ClockBase Agent uses LLMs to generate and test aging hypotheses across 2M+ samples. The measurement problem is being solved.
Nature Communications, 2023
Machine learning screened 4,340 compounds and discovered 3 novel senolytics -- a 100x cost reduction over wet-lab approaches. Graph neural networks have now predicted activity across 800,000+ molecules. More candidates found in 2 years than the previous decade of experiments.
Founder and CEO
15+ years in AI/ML. Former Head of AI Innovation at Motorola Solutions. Computational biology research at Bar-Ilan University (BINA) -- direct experience modeling complex biological systems and molecular dynamics. Founder of Ultra Deep Tech (AI safety lab). Deep reinforcement learning expertise from algorithmic trading at Geyser Light Capital. M.Sc. Industrial Engineering, B.Sc. Mathematics and Physics.
LinkedIn ProfileLongevity research has been dominated by wet-lab biologists who test one compound at a time. AI changes the game by screening millions of candidates, integrating multi-omics data, and designing novel interventions computationally. An AI-native founder with computational biology experience bridges the gap between ML capability and biological understanding -- exactly what the field needs to accelerate from academic curiosity to clinical impact.
Aging biology, senolytic drug discovery, epigenetics, cellular reprogramming, clinical gerontology
ML engineers, computational biologists, aging researchers. Get in touch
BioAge Explorer and Senolytic Screener live. First 500 researchers and biohackers on the platform.
Raise $1.5M. Hire founding ML engineer and computational biologist.
Enterprise screening API for pharma R&D. Multi-omics aging clock integration. Academic lab partnerships.
Raise $4M. AI-designed novel senolytic compounds. First wet-lab validation partnerships.
AI-designed reprogramming factors. Validated drug candidates. The standard platform for longevity AI.
Chronos Bio is in development. Join the waitlist to get early access to BioAge Explorer and Senolytic Screener. Longevity researchers and biotech professionals get priority.
Leave your email and we'll notify you when Chronos Bio launches.
No spam. Unsubscribe anytime.